Researchers at Concordia’s Department of Biology and Department of Chemistry and Biochemistry have discovered a possible new avenue of treatment that can help slow antibiotic resistance in bacteria.
PhD candidate Farhan Chowdhury and associate professor Brandon Findlay recently shared the results of their research in a recent paper published in the journal ACS Infectious Diseases. The researchers describe how a strain of the bacteria E. coli is left severely weakened after it has developed resistance to the antibiotic chloramphenicol (CHL). This weakness leaves the bacteria unable to adapt to other types of antibiotics.
Understanding the ways in which resistance impairments evolve can help clinicians better target pathogens in patients.
“Instead of relying on antibiotic cocktails, we can have an alternative where sequential antibiotic therapies are applied,” Chowdhury explains.
“Clinicians can select the sequence of medication by seeing if a first antibiotic imposes deficits on the bacteria, which would slow down the evolution of resistance in the subsequent ones. This can lead to better therapies and give patients more time to recover before resistance evolves.”